Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections
暂无分享,去创建一个
Charles A. Wartchow | Remo S. Schmidt | M. Barrett | J. Mottram | Yen-Liang Chen | A. Schenk | P. Mäser | J. Jiricek | Srinivasa P. S. Rao | Suresh B. Lakshminarayana | K. Wan | C. Osborne | M. Kaiser | C. Luu | J. Kelly | E. Myburgh | U. Manjunatha | C. Wartchow | Manuel Saldivia | Debjani Patra | T. Diagana | Vanessa Manoharan | J. Gable | Christopher Sarko | M. Gould | N. Wiedemar | R. S. Jumani | N. Aziz | P. Ng | J. Noeske | C. Deniston | O. René | Wilian A. Cortopassi | Bryanna Thomas | John Walker | A. Francisco | Nila Johnson | N. A. Ghafar | Whitney Barnes | Ryan Ritchie | Harry Cheung | Rima Palkar | J. Wagner | Jan Jiricek
[1] R. Tarleton,et al. Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates , 2022, Nature Microbiology.
[2] F. Gamo,et al. Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria , 2022, Journal of medicinal chemistry.
[3] I. Gilbert,et al. DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis , 2021, Journal of medicinal chemistry.
[4] V. Lamour,et al. Structural basis for allosteric regulation of Human Topoisomerase IIα , 2021, Nature Communications.
[5] N. Osheroff,et al. Topoisomerase II Poisons: Converting Essential Enzymes into Molecular Scissors. , 2021, Biochemistry.
[6] F. Supek,et al. Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases , 2020, Journal of medicinal chemistry.
[7] Christel Genoud,et al. Live Analysis and Reconstruction of Single-Particle Cryo-Electron Microscopy Data with CryoFLARE. , 2020, Journal of chemical information and modeling.
[8] M. Barrett,et al. New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story , 2020, Tropical medicine and infectious disease.
[9] F. Supek,et al. Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis , 2020, Tropical medicine and infectious disease.
[10] Sarah L. Williams,et al. Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors , 2019, bioRxiv.
[11] Juan A. Bueren-Calabuig,et al. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition , 2019, Proceedings of the National Academy of Sciences.
[12] G. Dranoff,et al. Drug Discovery for Kinetoplastid Diseases: Future Directions. , 2018, ACS infectious diseases.
[13] Michael D. Urbaniak,et al. Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis , 2018, Nature.
[14] David Horn,et al. Inducible high-efficiency CRISPR-Cas9-targeted gene editing and precision base editing in African trypanosomes , 2018, Scientific Reports.
[15] Mark C. Field,et al. Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei , 2018, PLoS neglected tropical diseases.
[16] G. Bonamy,et al. Development of a Cytopathic Effect-Based Phenotypic Screening Assay against Cryptosporidium. , 2018, ACS infectious diseases.
[17] Tun-Cheng Chien,et al. Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry , 2017, Nucleic acids research.
[18] Joseph H. Davis,et al. Addressing preferred specimen orientation in single-particle cryo-EM through tilting , 2017, Nature Methods.
[19] Glen Spraggon,et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness , 2016, Nature.
[20] F. Supek,et al. Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease , 2015, PLoS pathogens.
[21] M. Barrett,et al. Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi Revealed by Metabolomics , 2014, PLoS neglected tropical diseases.
[22] M. Miles,et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection , 2014, Cellular microbiology.
[23] Hemant D. Tagare,et al. The Local Resolution of Cryo-EM Density Maps , 2013, Nature Methods.
[24] Michael P. Barrett,et al. In Vivo Imaging of Trypanosome-Brain Interactions and Development of a Rapid Screening Test for Drugs against CNS Stage Trypanosomiasis , 2013, PLoS neglected tropical diseases.
[25] B. Schmidt,et al. Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity , 2012, Nature Structural &Molecular Biology.
[26] D. Horn,et al. Trypanosomal histone γH2A and the DNA damage response , 2012, Molecular and biochemical parasitology.
[27] R. McCulloch,et al. Trypanosoma brucei BRCA2 acts in antigenic variation and has undergone a recent expansion in BRC repeat number that is important during homologous recombination , 2008, Molecular microbiology.
[28] J. Barry,et al. A role for RAD51 and homologous recombination in Trypanosoma brucei antigenic variation. , 1999, Genes & development.
[29] Detlef D. Leipe,et al. Toprim--a conserved catalytic domain in type IA and II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins. , 1998, Nucleic acids research.
[30] B. Schmidt,et al. A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases , 2010, Nature.